Top Markets
#1 MowCat MowCat +48.95%
#2 Bermuda Shorts Bermuda Shorts +25.87%
#3 Velvet Velvet +24.42%
#4 Audiera Audiera +22.52%
#5 aPriori aPriori +20.79%
#6 Derive Derive +20.37%
#7 Biconomy Biconomy +18.03%
#8 Quack AI Quack AI +17.31%
#9 Geodnet Geodnet +11.94%
#10 Palladium Network Palladium Network +10.99%
Coin of the day
MowCat MowCat
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
IMV Inc. IMV Inc.

IMV Inc.

IMV
Pozycja w akcjach #35289
IMV Inc. is a clinical-stage biotechnology company dedicated to the development... IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.
Cena akcji
$0.82959892
Ostatnia synchronizacja: 2023-05-23
Kapitalizacja rynkowa
$4.16M
Zmiana (1 dzień)
-0.04%
Zmiana (1 rok)
0.00%
Kraj
CA
Handel IMV Inc. (IMV)

Kategoria

Healthcare
Zyski dla IMV Inc. (IMV)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych IMV Inc., obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy IMV Inc. od 2026 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
Za mało danych dla podanych dat.
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE